Oklahoma City, OK 73105
For Immediate Release:
February 12, 2007
Senator Charles Laster
Senate Committee Okays Bill Banning Sale
of Cough Medicine/Spray Paint to Minors
The Senate Business and Labor Committee on Monday
gave approval to a bill that would ban the sale of cough medicine
containing dextromethorphan (DXM) as well as spray paint to anyone
under the age of 18. State Sen. Charlie Laster is author of Senate
“The recommendations in this bill come directly from the Task
Force on Adolescent Substance Abuse and Misuse of Household Items.
We found out how Oklahoma kids are able to buy large quantities
of these items to get high with no legal restrictions,” said
Laster, D-Shawnee. “This is a dangerous problem we need to
At high doses, dextromethorphan acts as a powerful hallucinogen.
Nationally in 2004, there were an estimated 12,584 emergency room
visits because of products with DXM. In this state, the Oklahoma
Poison Control Center reports that DXM abuse is on the rise. In
2006, 14.7 percent of all reported intentional substance abuse cases
in Oklahoma were DXM, compared to 11.6 percent in 2005.
Inhalant use, such as spray paint, is also up among Oklahoma youth.
In 2003, 9.9 percent of youths grades 9-12 reported using inhalants,
compared to 12 percent in 2005.
“If SB 951 becomes law, it would be a misdemeanor to sell
those products to any one under 18,” Laster said. “In
addition, the legislation makes it illegal for anyone to sell or
provide unfinished DXM to anyone other than a purchaser licensed
by the U.S. Food and Drug Administration.”
The legislation would also require those possessing or selling unfinished
DXM, which is used in manufacturing, to register with the Oklahoma
Bureau of Narcotics and Dangerous Drugs.
“Our number one goal is to keep Oklahoma children safe, and
that means making sure our laws are updated to address these new
threats to their very lives,” Laster said. “That means
we have to redefine what we consider to be dangerous drugs—that’s
what my legislation does.”
SB 951 now moves to the full Senate for consideration.
For more information contact:
Senator Laster's Office - (405) 521-5539